Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar someicg (41.88) Submitted: 2/6/2012 12:25:24 AM : Underperform Start Price: $2.37 CRME Score: +21.96

inverse tort screen

Featured Broker Partners


Advertisement